Network Meta-Analysis of Biological Response Modifiers in Rheumatoid arthritis Including real World Evidence at Multiple time Points

Network meta-analysis (NMA) is widely used to compare multiple interventions of interest when head-to-head comparisons of active treatments are not available. Most NMAs pool data from randomised controlled trials (RCTs) on a single clinical outcome. However, in the case of chronic diseases such as rheumatoid arthritis (RA), outcomes are often reported at different time points and long-term real-world data (RWD) is routinely collected as part of national registries. Evaluation of models for the inclusion of different time measures in NMA, especially from both a regulatory and reimbursement perspective, is thus warranted and is considered here.